urology

How to command patient trust while building experienceWhile questions about experience can be uncomfortable for new surgeons, Nirmish Singla, MD, believes the process of mastering procedures is invaluable to conveying the confidence necessary to help patients feel comfortable.
VA rule on APRNs places veterans’ health first“The evidence is clear: Not only can APRNs practice independently, they can do so effectively and without sacrificing quality of care,” writes SUNA President Gwendolyn Hooper, PhD, APRN.
What will replace the Affordable Care Act?President Trump’s campaign promise to “repeal and replace” the Affordable Care Act has proved to be easier said than done as Republicans who control Congress have been unable to devise a workable and acceptable replacement for the controversial health care law.
Cyclosporine shows efficacy in refractory IC patientsOral cyclosporine can offer a safe and effective treatment option for refractory interstitial, even in patients who have been on chronic narcotic medications and particularly in those with Hunner’s lesions, according to the findings of a study presented by Cleveland Clinic urologists at the 2016 AUA annual meeting in San Diego.
What is the biggest stressor in your office?Three urologists discuss what causes them the most angst and the ways they try to reduce the pressure.
From seller to buyer: Tips for a smooth transitionNeil Baum, MD, and Randy Bauman discuss their tips to making the transition from practice seller to buyer as seamless as possible to keep patient retention rates high.
PD-1 inhibitor benefit possible even after discontinuationPersistent clinical benefit was seen among a small group of patients with metastatic renal cell carcinoma who had to discontinue therapy with the PD-1 inhibitor nivolumab (Opdivo) because of immune-related adverse events, according to a study presented at the Genitourinary Cancers Symposium in Orlando, FL.
Antibiotics may negatively impact immunotherapy outcomesAdministration of broad-spectrum antibiotics in patients with metastatic renal cell carcinoma (RCC) undergoing treatment with immune checkpoint inhibitors may have a negative effect on the efficacy of the immunotherapy drugs, according to the results of a recent retrospective analysis.
Novel bladder Ca agent shows promise in phase II trialAn investigatory bladder cancer agent was associated with a 12-month high-grade recurrence-free survival of 35% for patients with Ta/T1 disease, researchers reported.
Rheumatologic side effects possible with immunotherapiesCancer patients taking certain immunotherapy drugs may be more susceptible to developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a recent study.